64 completed, 26 unknown, 21 recruiting, 14 terminated. 144 Phase 3, 29 Phase 2.
Follow Liver Cirrhosis: new trials by email Literature Review of Liver Cirrhosis trials Research Report on Liver Cirrhosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 1500 | 2026-11-06 | 2026-10-02 |
| Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni | Phase 2 / Phase 3 | Not yet recruiting | Rhode Island Hospital | 600 | 2026-11-01 | 2026-08-12 |
| J-LINX: Japan LINerixibat eXtension Study Linerixibat - Pruritus | Phase 3 | Not yet recruiting | GlaxoSmithKline | 40 | 2026-10-09 | 2026-10-06 |
| Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy Saroglitazar Magnesium 1 mg, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Zydus Therapeutics Inc. | 90 | 2026-08-11 | 2026-09-15 |
| Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial Apixaban 2.5 mg twice daily, Placebo - Liver Cirrhosis | Phase 3 | Not yet recruiting | University College, London | 1142 | 2026-07-15 | 2026-07-24 |
| Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial Low-dose aspirin, Placebo Comparator - Liver Cirrhosis | Phase 3 | Not yet recruiting | Curtin University | 890 | 2026-06-01 | 2026-04-14 |
| Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes Saroglitazar magnesium 1 mg, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Zydus Therapeutics Inc. | 386 | 2026-03-24 | 2026-08-04 |
| A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B. Hydronidone (270mg), Hydronidone (Placebo Group) - Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B | Phase 3 | Not yet recruiting | Beijing Continent Pharmaceutical Co, Ltd. | 1208 | 2026-01-30 | 2026-02-17 |
| FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy Fenofibrate, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Phase 3 | Recruiting | Xijing Hospital of Digestive Diseases | 132 | 2025-12-15 | 2025-12-29 |
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA 2mg CS0159, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Cascade Pharmaceuticals, Inc | 135 | 2025-12-01 | 2026-07-08 |
| Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis Dabigatran, Enoxaparin - Portal Vein Thrombosis, Liver Cirrhosis | Phase 2 / Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 120 | 2025-01-31 | 2025-02-10 |
| A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) Elafibranor - Primary Biliary Cholangitis | Phase 3 | Active not recruiting | Ipsen | 18 | 2025-01-16 | 2026-10-23 |
| A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics Prednisone, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Phase 2 / Phase 3 | Enrolling by invitation | Han Ying | 244 | 2024-10-30 | 2026-10-29 |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis Survodutide, Placebo - Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis | Phase 3 | Recruiting | Boehringer Ingelheim | 1800 | 2024-10-14 | 2026-10-28 |
| Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis Fecal microbiota transplantation - Liver Cirrhosis | Phase 3 | Completed | Cristian Ichim | 19 | 2024-08-05 | 2026-03-27 |
| Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis Saroglitazar Magnesium 1 mg - Primary Biliary Cholangitis | Phase 3 | Active not recruiting | Zydus Therapeutics Inc. | 102 | 2024-07-16 | 2026-05-12 |
| A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. Elafibranor, Placebo - Primary Biliary Cholangitis | Phase 3 | Completed | Ipsen | 92 | 2024-07-09 | 2026-07-09 |
| To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate FDC tablet (OCA 5 mg + BZF 400 mg SR) - Primary Biliary Cholangitis | Phase 3 | Terminated | Intercept Pharmaceuticals | 62 | 2024-07-01 | 2026-06-08 |
| Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study Fenofibrate in Combination With Ursodeoxycholic Acid - Primary Biliary Cholangitis (PBC) | Phase 3 | Recruiting | Xijing Hospital of Digestive Diseases | 150 | 2024-01-30 | 2026-01-08 |
| Fenofibrate in Primary Biliary Cholangitis: a Real World Study Fenofibrate - Primary Biliary Cholangitis (PBC) | Phase 3 | Recruiting | Xijing Hospital of Digestive Diseases | 300 | 2024-01-17 | 2026-01-08 |
Showing 20 of 144. Sign in to see all of them.
Liver Cirrhosis, Biliary (44) · Fibrosis (23) · Ascites (14) · Hypertension, Portal (12) · Hepatitis C (11) · Hepatitis C, Chronic (10) · Esophageal and Gastric Varices (8) · Carcinoma, Hepatocellular (5) · Hepatic Encephalopathy (5) · Non-alcoholic Fatty Liver Disease (5) · Cholestasis (4) · Liver Diseases (3) · Metabolic Syndrome (3) · Obesity (3)
Pathological Conditions, Signs and Symptoms (144) · Pathologic Processes (143) · Digestive System Diseases (142) · Liver Diseases (141) · Fibrosis (121) · Bile Duct Diseases (44) · Biliary Tract Diseases (44) · Cholestasis, Intrahepatic (44) · Cholestasis (40) · Infections (20) · Blood-Borne Infections (17) · Communicable Diseases (17) · Flaviviridae Infections (17) · Hepatitis (17)
Ribavirin (9) · Ursodeoxycholic Acid (9) · Fenofibrate (8) · peginterferon alfa-2b (7) · Rifaximin (6) · Propranolol (5) · seladelpar (5) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (4) · peginterferon alfa-2a (4) · saroglitazar (4) · Bezafibrate (3) · Calcium Carbonate (3) · Methotrexate (3) · Norfloxacin (3) · hydronidone (3)
Xijing Hospital of Digestive Diseases (10) · Merck Sharp & Dohme LLC (6) · Gilead Sciences (5) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · Ipsen (4) · Post Graduate Institute of Medical Education and Research, Chandigarh (4) · Sherief Abd-Elsalam (4) · Tanta University (4) · Zydus Therapeutics Inc. (4) · Beijing Continent Pharmaceutical Co, Ltd. (3) · GlaxoSmithKline (3) · Sanofi (3) · Assistance Publique - Hôpitaux de Paris (2) · Han Ying (2) · Hospital Clinic of Barcelona (2)
United States (32) · China (30) · Spain (25) · Italy (23) · France (22) · Germany (19) · United Kingdom (19) · Belgium (17) · Canada (17) · Argentina (14) · South Korea (13) · Australia (11) · Czechia (11) · Poland (11) · Romania (11)
Sherief M. Abd-Elsalam, Consultant (3) · Eric Bellissant, MD, PhD (2) · Virendra Singh, DM (2) · Walaa A. Elkhalawany, Consultant (2) · A. K. Singal, Professor (1) · Abeer El-Motwally, Msc (1) · Abhasnee Sobhonslidsuk, MD (1) · Adrian Boicean, Prof. Dr. (1) · Adrian M. Di Bisceglie, M.D. (1) · Adrian Reuben, M.D. (1) · Akmal Taher (1)
PMID 21836029, PMID 25543678, PMID 10051462, PMID 10343514, PMID 10347106, PMID 12360466, PMID 14630883, PMID 15017671, PMID 15128074, PMID 15468571, PMID 16299032, PMID 16306522, PMID 16530513, PMID 16848809, PMID 16863557, PMID 17133492, PMID 17399846, PMID 18045724, PMID 18237873, PMID 18752324, PMID 18848939, PMID 19052125, PMID 19291787, PMID 19302262, PMID 19303163, PMID 19445938, PMID 19554543, PMID 19676128, PMID 19747918, PMID 19766643, PMID 19782361, PMID 19852963, PMID 19940555, PMID 20070284, PMID 20211180, PMID 20362695, PMID 20564351, PMID 20621200, PMID 20675008, PMID 20675691, PMID 20849805, PMID 20889211, PMID 20953964, PMID 21056496, PMID 21083592, PMID 21129375, PMID 21139575, PMID 21157444, PMID 21335007, PMID 21374690
2005 (2), 2019 (2), 2014 (1), 2023 (1), R01AI184979 (1), R01DK046580 (1), R01DK046602 (1), R01DK051523 (1)